Business
Are All Hallucinogens Psychedelics and Are All Psychedelics Hallucinogens?
Are all psychedelics hallucinogens and vice versa?
We are experiencing a period of change where previously prohibited and stigmatized substances are receiving favorable attention from the public. From ketamine to cannabis to magic mushrooms, the discourse has shifted from prohibition to determining the optimal ways to utilize these substances. Our write up on the Bengzina Psychedelics show from Miami this year is a hot take, so check it out here.
However, it can be perplexing to differentiate between the terminologies, especially in psychedelics. For many, the question that needs an answer is every psychedelic a hallucinogen, and are all hallucinogens psychedelics? Keep reading to learn more.
Why Simplify Terminologies?
Before we delve into the nuances that differentiate “psychedelics” from “hallucinogens,” let’s ponder how ideas and terminologies often undergo simplification or distortion due to misunderstandings. Let’s face it, we’re not all experts in every field. When a news item gains widespread attention, it is often simplified to ensure that the general public can comprehend it, even if this means diluting or slightly altering its original definition.
Hallucinogens and Psychedelics
As we have already established, simplifying ideas and confusing terms is a common practice to make concepts more accessible to a non-expert public. This notion raises the question of whether all hallucinogens can be regarded as psychedelics, especially in this modern era of drug acceptance. The term “psychedelics” is often attributed with meanings surpassing its definition.
Consider ketamine, which has gained significant prominence with the increasing popularity of psychedelic therapy. However, ketamine is not a psychedelic despite being referred to as one, even on websites offering ketamine services. This misnomer is not intended to be misleading but to simplify the language for better understanding without overwhelming the audience with complex categorical terms. In truth, ketamine is a dissociative hallucinogen.
Psychedelics are a class of psychoactive substances known for producing profound changes in consciousness, perception, and mood. These substances alter an individual’s sensory experiences, often inducing visual and auditory hallucinations, changes in time perception, and a sense of self-transcendence or ego dissolution. The term “psychedelic” was first coined in the 1950s by British psychiatrist Humphry Osmond, who used it to describe the mind-altering effects of certain substances.
“Psychedelics” exclusively refers to four compounds: DMT, psilocybin, mescaline, and LSD. Although they each have distinct modes of action, they share the common feature of being agonists at serotonin receptors, specifically 5-HT2A. This classification is based on their method of action. On the other hand, is ketamine a serotonergic drug? No, it isn’t. Dissociative hallucinogens, such as DXM and PCP, primarily affect dopamine and NMDA receptors, albeit with their unique actions.
The classification of ketamine as a hallucinogen is evident in its class name. This illustrates that ketamine can be categorized as a hallucinogen without being psychedelic, indicating that not all hallucinogens fall under the classification of psychedelics. In fact, the four compounds recognized as psychedelics are often referred to as “classical psychedelics,” a term coined to reclassify them in the face of growing confusion regarding the true meaning of psychedelic drugs.
What Are Hallucinogens?
Hallucinogens encompass various types of drugs that share the ability to induce an altered state of mind. Significant shifts in mood, thought, and perception of one’s surroundings and self are examples. After all, a hallucination is an experience of something false or altered in our perception. This can include sensing or tasting something that isn’t there or experiencing something otherwise as it ought to be.
The effects of hallucinogens can vary widely depending on the individual, the substance, and the dosage. Some users report euphoria, enhanced creativity, and spiritual experiences, while others may experience anxiety, paranoia, and other adverse psychological effects. In some cases, hallucinogen use can lead to a phenomenon known as a “bad trip,” in which the user experiences intense anxiety, confusion, or paranoia.
The classification structure generally divides hallucinogens into three types: psychedelics (DMT, LSD, psilocybin, mescaline), dissociatives (ketamine, DXM, PCP), and deliriants (datura, Benadryl). The final group significantly affects the neurotransmitter acetylcholine, distinguishing its mode of action from the other two groups.
The classification of hallucinogens is not a neat and tidy affair, and plenty of substances fall outside the standard groupings. For instance, take Amanita muscaria mushrooms. While classified as poisonous mushrooms, they can produce potent hallucinations and interact with GABA receptors. Additionally, substances like MDMA and 2C-B are often lumped in with psychedelics, but they belong to psychostimulants and phenethylamines, respectively. Despite this, they can still induce hallucinations.
And then there’s salvia, a member of the Lamiaceae mint family with no taxonomic classification for its hallucinogenic properties. Salvia is the only known diterpene hallucinogen, making it a distinctive member of the hallucinogen family. It shares some structural similarities with cannabis components but differs dramatically from them. Given that it doesn’t target the 5-HT2A receptors, often linked to traditional psychedelics, its mode of action is still relatively mysterious. Instead, it appears to engage D2 (dopamine) receptors and -opioid receptors. Despite having hallucinatory properties, it is not psychedelic.
One inference we can draw from this is that although not all hallucinogens fall under the category of psychedelics, all psychedelics are indeed hallucinogens, along with many other non-psychedelic drugs. The term “hallucinogens” encompasses a wide range of psychoactive substances that can induce altered states of perception, regardless of their specific chemical structure or mode of action.
Conclusion
The world of hallucinogens is complex and diverse, with many different substances and classifications. While the term “psychedelic” is often used interchangeably with “hallucinogen,” it’s essential to recognize that not all hallucinogens are psychedelics, and not all psychedelics are hallucinogens. The classical psychedelics, which include DMT, psilocybin, mescaline, and LSD, are characterized by their action on serotonin receptors, specifically 5-HT2A.
Other classes of hallucinogens include dissociatives, such as ketamine, DXM, and PCP, which primarily act on dopamine and NMDA receptors. Deliriants, such as Datura and Benadryl, significantly impact the neurotransmitter acetylcholine. Other substances, like salvia and Amanita muscaria mushrooms, also produce hallucinogenic effects but don’t fit neatly into any category.
It’s worth noting that while the effects of hallucinogens can be profound and life-changing for some, they can also be unpredictable and potentially dangerous. Proper education, preparation, and harm reduction measures are crucial for anyone considering these substances.
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy